Spots Global Cancer Trial Database for 6mhp
Every month we try and update this database with for 6mhp cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma | NCT02425306 | Melanoma | 6MHP Montanide ISA-5... polyICLC Cyclophosphamid... | 18 Years - | University of Virginia | |
Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma | NCT02425306 | Melanoma | 6MHP Montanide ISA-5... polyICLC Cyclophosphamid... | 18 Years - | University of Virginia | |
A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma | NCT02385669 | Melanoma | Ipilimumab 6MHP | 18 Years - | University of Virginia | |
A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib | NCT02382549 | Melanoma | BRAF inhibitor 6MHP MEK inhibitor | 18 Years - | University of Virginia | |
A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib | NCT02382549 | Melanoma | BRAF inhibitor 6MHP MEK inhibitor | 18 Years - | University of Virginia | |
Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma | NCT03617328 | Melanoma | 6MHP Montanide ISA-5... polyICLC CDX-1127 | 18 Years - | University of Virginia | |
Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) | NCT04364230 | Melanoma Ocular Melanoma Uveal Melanoma | 6MHP NeoAg-mBRAF PolyICLC CDX-1140 | 18 Years - | University of Virginia | |
Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) | NCT04364230 | Melanoma Ocular Melanoma Uveal Melanoma | 6MHP NeoAg-mBRAF PolyICLC CDX-1140 | 18 Years - | University of Virginia | |
Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab | NCT02515227 | Melanoma | 6MHP Pembrolizumab | 18 Years - | University of Virginia |